SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · The SEC declared effective Spero Therapeutics' S-3 shelf registration…

Spero Therapeutics, Inc. · EFFECT filed Sep 11, 2026 at 00:15 ET

At the news

BEARISHIMPACT 7/10

EFFECT filed Sep 11, 2026 at 00:15 ET

The SEC declared effective Spero Therapeutics' S-3 shelf registration (File No. 333-298641) on September 10, 2026, enabling the company to sell up to $300M in securities, including an immediate $100M at-the-market (ATM) common stock offering via Jefferies. This follows a prior S-3 filing 14 days ago and comes at a $68M market cap for a clinical-stage biotech with no approved products, making the ATM size (1.4x market cap) massively dilutive. The effectiveness removes the final regulatory barrier for a dilutive capital raise to fund preclinical development of SP001, with no near-term revenue prospects.

  • S-3 shelf registration (File No. 333-298641) declared effective on September 10, 2026
  • Registration covers up to $300M in securities, including an immediate $100M ATM offering
  • ATM size ($100M) is approximately 1.4x the company's $68M market cap
  • Spero is a clinical-stage biotech with no approved products and no near-term revenue

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access